<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893539</url>
  </required_header>
  <id_info>
    <org_study_id>ISI-ION-001-2018</org_study_id>
    <nct_id>NCT03893539</nct_id>
  </id_info>
  <brief_title>Clinical Utility for Ion Endoluminal System</brief_title>
  <official_title>PRECIsE: A Prospective Evaluation of the Clinical Utility for the Ion Endoluminal System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuitive Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intuitive Surgical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this prospective, multi-center, single-arm, clinical study is to evaluate the&#xD;
      clinical utility and performance of the FDA-cleared Ion™ Endoluminal System (&quot;Ion&quot;) for&#xD;
      bronchoscopically approaching and facilitating the tissue sampling of pulmonary nodules.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Navigation Success</measure>
    <time_frame>Day 1 (Time of Procedure)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy Success</measure>
    <time_frame>Day 1 (Time of Procedure)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity for Malignancy of System-Obtained Sample</measure>
    <time_frame>14 months Post-Procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Intra-procedure, Immediately Post-Procedure, Day 10 Post-Procedure, Day 30 Post-Procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Pulmonary Nodule</condition>
  <condition>Lung Cancer</condition>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>Robotic Bronchoscopy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Ion™ Endoluminal System assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion™ Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ion Endoluminal System™</intervention_name>
    <description>The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.</description>
    <arm_group_label>Robotic Bronchoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years and older&#xD;
&#xD;
          -  Patient is suitable for elective bronchoscopy&#xD;
&#xD;
          -  Patients with a moderate to high risk of lung cancer based on clinical, demographic&#xD;
             and radiologic information or with suspected metastatic disease&#xD;
&#xD;
          -  Solid or semi-solid pulmonary nodules of ≥ 1cm and ≤ 3cm in largest dimension&#xD;
&#xD;
          -  Nodule is located in bronchial generation 4+ (i.e. beyond segmental bronchus*&#xD;
&#xD;
          -  Patients are candidates for CT-guided needle biopsy and/or surgical resection&#xD;
&#xD;
          -  Patient able to understand and adhere to study requirements&#xD;
&#xD;
          -  Patient able to understand and adhere to study requirements and able to provide&#xD;
             informed consent&#xD;
&#xD;
          -  Patient not legally incapacitated or in legal/court ordered institution&#xD;
&#xD;
          -  Patients with no dependency on the investigator or sponsor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of fitness or exercise capacity to undergo bronchoscopy under general anesthesia&#xD;
             as determined by physician prior to procedure&#xD;
&#xD;
          -  Acute myocardial infarction or unstable angina ≤ 6 weeks prior to study procedure&#xD;
&#xD;
          -  Clinically relevant partial trachea obstruction or obstruction of vena cava per&#xD;
             physician assessment&#xD;
&#xD;
          -  Acute respiratory failure, clinically significant hypoxemia, or high respiratory rate&#xD;
             (i.e.&gt; 30 breaths per minute) per physician assessment)&#xD;
&#xD;
          -  Renal insufficiency that presents risk per physician's discretion or liver failure&#xD;
             (i.e. CHILD-PUGH Class C)&#xD;
&#xD;
          -  World Health Organization functional Class III or Class IV Pulmonary Hypertension or&#xD;
             history of clinically significant mPAP&#xD;
&#xD;
          -  Lung abscess&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
&#xD;
          -  Recent head injury (&lt;12 weeks pre-procedure) or subjects presenting with clinically&#xD;
             significant neurologic deficits&#xD;
&#xD;
          -  Unstable hemodynamic status (i.e. Dysrhythmia requiring intervention, altered mental&#xD;
             status/consciousness)&#xD;
&#xD;
          -  Subjects with pure ground glass opacity target nodule&#xD;
&#xD;
          -  Inability to adequately oxygenate subject during procedure per physicians discretion&#xD;
             (i.e. unable to achieve S02 &gt; 92% or requiring &gt;4L of oxygen prior to procedure)&#xD;
&#xD;
          -  Subject with uncorrectable coagulopathy, bleeding or platelet disorders, history of&#xD;
             major bleeding with bronchoscopy&#xD;
&#xD;
          -  Subjects contraindicated for intubation or general anesthesia, or subjects with ASA ≥&#xD;
             4&#xD;
&#xD;
          -  Subjects taking antiplatelet (i.e. clopidogrel), anti-coagulant (i.e heparin or&#xD;
             warfarin) or platelet aggression inhibitors (i.e. Abciximab or Eptifibatide)&#xD;
             medications that cannot be stopped per standard practice, i.e. 5-7 days pre-procedure&#xD;
             or heparin that cannot be held according to standard practice (6-12 hours). Aspirin&#xD;
             not included.&#xD;
&#xD;
          -  Any severe or life-threatening comorbidity that could increase the risk of&#xD;
             bronchoscopic biopsy (i.e. &gt;Stage 3 heart failure)&#xD;
&#xD;
          -  Moderate-to-severe pulmonary fibrosis presenting procedural risk as assessed by&#xD;
             physician&#xD;
&#xD;
          -  Endobronchial lesion associated with lobar atelectasis&#xD;
&#xD;
          -  Presence of bullae &gt;1cm located within a cone based trajectory of biopsy instruments&#xD;
             or in location presenting risk per physician assessment&#xD;
&#xD;
          -  Known allergy, sensitivity or previous allergic reaction to ortho-phthalaldehyde (OPA)&#xD;
&#xD;
          -  Subjects taking the following medications: Immunosuppressive treatment with systemic&#xD;
             azathioprine, Cyclosporine, antibodies or cytostatics, other chemotherapeutic agents&#xD;
             or medications acting on immunophilins&#xD;
&#xD;
          -  Non-systemic treatment for lung cancer (i.e. SBRT, ablation) performed in the same&#xD;
             lobe as the target nodule(s)&#xD;
&#xD;
          -  Previous surgical intervention (i.e. wedge resection or lobectomy) within the same&#xD;
             lobe as target nodule (s)&#xD;
&#xD;
          -  Participation in any interventional clinical study or clinical study with experimental&#xD;
             agents or agents of unknown risk in last 30 days prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Folch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiba Lejmi, MD</last_name>
    <phone>408-523-7202</phone>
    <email>Hiba.Lejmi@intusurg.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sundeep Master, MS</last_name>
    <phone>408-523-1045</phone>
    <email>Sundeep.Master@intusurg.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Folch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Erik E Folch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colleen Keyes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Majid, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mihir Parikh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Simoff, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Diaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>FirstHealth Moore Regional Hospital</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ost, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Ost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Casal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

